Octreotide seems to have a beneficial effect on variceal bleeding, and long-term administration for the prevention of rebleeding is currently being evaluated. Experimental studies have suggested a beneficial effect of chronic octreotide treatment on renal function, while clinical studies have shown variable effects. Twenty-five cirrhotic patients with portal hypertension were randomized in a double-blind design to placebo or a single subcutaneous dose of a long-acting formulation of octreotide (octreotide-LAR) (20 mg). Renal function tests were performed before dosing and repeated after 30 days. The patients were in sodium steady state at the time of study. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by a constant infusion clearance technique. Renal sodium handling was determined by lithium and sodium clearance measurements. Therapeutic serum levels of octreotide along with a reduction of insulin-like growth factor I (IGF-I) (P < .01) and an increase of IGF binding protein 1 (P < .05) were demonstrated. No effect of octreotide was observed on GFR, ERPF, or filtration fraction (GFR/ERPF). Changes in clearance and extraction fraction of sodium and lithium during octreotide treatment were not significantly different from those of placebo. In addition, no changes in free water clearance, urinary flow rate, or 24-hour Na excretion were demonstrated. A significant increase of mean arterial pressure (+5 mm Hg; P < .01) was observed after treatment with octreotide-LAR. It is concluded that in spite of increased arterial pressure, octreotide-LAR has no significant effect on renal hemodynamics and tubular function in clinically stable cirrhotic patients with portal hypertension. (Hepatology 2001;34:471-477.)
This study aimed to determine whether obese men with nonalcoholic fatty liver disease (NAFLD) display differences between those with simple steatosis versus steatohepatitis (NASH) in splanchnic and hepatic FFA and VLDL-triglycerides (VLDL-TG) balances. The study involved 17 obese men with biopsy-proven NAFLD (9 with NASH and 8 with simple steatosis). We used hepatic vein catheterization in combination with [H-3]palmitate and [C-14] VLDL-TG tracers to measure splanchnic palmitate and VLDL-TG uptake and release rates during basal and hyperinsulinemic conditions. Indocyanine green was used to measure splanchnic plasma flow. Splanchnic palmitate uptake was similar in the two groups and significantly reduced during hyperinsulinemia (NASH: 62 (48 -77) versus 38 (18 -58) mu mol/min; simple steatosis: 62 (46 -78) versus 45 (25 -65) mu mol/min, mean (95% CI), basal versus clamp periods, respectively, P = 0.02 time-effect). Splanchnic palmitate release was also comparable between groups and nonsignificantly diminished during hyperinsulinemia. The percent palmitate delivered to the liver originating from visceral adipose tissue lipolysis was similar and unchanged by hyperinsulinemia. Splanchnic uptake and release of VLDL-TG were similar between groups. Hyperinsulinemia suppressed VLDL-TG release ( P <0.05 time-effect) in both groups. Insulin-mediated glucose disposal was similar in the two groups ( P = 0.54). Obese men with NASH and simple steatosis have similar splanchnic uptake and release of FFA and VLDL-TG and a similar proportion of FFA from visceral adipose tissue lipolysis delivered to the liver. These results demonstrate that the splanchnic balances of FFA and VLDL-TG do not differ between obese men with NASH and those with simple steatosis.
16 January 2026 in Cochrane Database of Systematic Reviews
Impaired lung function is more common among liver transplant recipients than the general population, but the pathogenesis is unknown. We investigated whether prior CMV infections are associated with impaired lung function in liver transplant recipients. We invited adult liver transplant recipients from The Danish Comorbidity in Liver Transplant Recipients study (DACOLT) for spirometry and collected data from systematic CMV screening for serostatus and DNAemia. Using linear and logistic regressions adjusted for age, sex, cumulative smoking, and use of inhalation medication, we assessed if prior CMV infections were associated with airflow limitation (FEV 1 /FVC < 0.7 and FEV 1 < 80% of expected) and FEV 1 . Of all eligible liver transplant recipients in Denmark, DACOLT included 600 (79%), and 356 fulfilled the substudy‐specific inclusion criteria. In adjusted models, pretransplant CMV seropositivity was not associated with either airflow limitation (aOR 2.18 [95% CI: 0.71–6.62]) or lower FEV 1 (adjusted β [a β ] = −60 [95% CI: −210 to 80] mL). The same applied to associations between prior CMV DNAemia and airflow limitation (aOR 0.91 [95% CI: 0.35–2.35]) as well as FEV 1 (a β = 30 [95% CI: −120 to 180] mL). This suggests limited clinical impact of CMV infection on posttransplant lung function in liver transplant recipients.